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Background: The effects of fascin on cell invasiveness involve changes in cell motility and matrix metalloproteinase-9
(MMP-9) activity. Previous studies on the prognostic value of fascin and MMP-9 in breast carcinoma revealed conflicting
results. To date, no immunohistochemical studies have been performed to assess the possible association between
them in breast carcinoma. This study is designed to correlate their expression with prognostic parameters in breast
carcinoma and assess the relationship between them.
Methods: Immunohistochemical expression of fascin and MMP-9 was evaluated semi quantitatively in 67 cases of
breast carcinoma regarding the percentage of positive cells. Chi square test and Fisher’s exact test were used to
examine the relationship between categorical variables. Kappa statistics was used to compute the measure of
agreement between two investigational methods.
Results: Fascin and MMP-9 expressions were detected in 43.28% and 50.75% of breast carcinomas (respectively).
Regarding the normal breast tissue, fascin expression was observed in myoepithelial cells and luminal cells of few
ducts and acini. However, normal tissue showed negative MMP-9 expression. A significant relationship was observed
between fascin and MMP-9 expression and lymph node metastases (p = 0.001 and 0.002 respectively), advanced tumor
stage (p = 0.004 and 0.005 respectively), estrogen receptor negative (p = 0.002 and 0.005 respectively), progesterone
receptor negative (p = 0.001 and 0.003 respectively) hormonal status and molecular subtypes (p = 0.0007 and 0.014
respectively). A significant strong agreement was detected between fascin and MMP-9 expression (p = 0.0001). More
intense immunostaining of fascin and MMP-9 was observed at the invasive fronts compared with other areas of the
tumor. Moreover, a significant moderate agreement between fascin and MMP-9 was found regarding the site of
predominant intensity.
Conclusion: Fascin and MMP-9 proteins are associated with parameters of poor prognosis in breast cancer. The
significant strong agreement between the two markers supports the role of fascin in cell invasiveness by activating
matrix proteases besides increasing cell motility. Both proteins may represent potential therapeutic targets for patients
with breast cancer especially those with hormone receptor–negative status.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1421167695121127.
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Breast cancer is one of the leading causes of cancer mor-
tality in women worldwide. In spite of significant advances
in cancer treatment, mortality results from local invasion
and/or distant metastasis and not from the tumor in the
primary site [1]. Tumor invasion and metastasis are the
results of several sequential steps and in part are caused
by the highly motile properties of tumor cells to overcome
cell-cell and cell matrix adhesion and to invade surround-
ing tissue. Invasive tumor cells often show specific mor-
phologic features, such as the appearance of membrane
protrusions as well as loss of cell-cell adhesion and loss of
junctional communications. These features are thought to
result from rearrangements of the cytoskeletal microfila-
ments by the action of actin cross-linking proteins [2].
Fascin, also known as fascin-1, is a 55-kDa globular actin
bundling protein [3] originally found in the extracts of
unfertilized sea urchin eggs and localized to the microfila-
ment bundles within microvilli cores and within filo podia
on the surface of fertilized sea urchin eggs [4]. In mamma-
lian cells, fascin is present in membrane ruffles, micro
spikes, and other motility-associated cell fibers [5]. It is a
key regulator of the actin cytoskeleton and is the leading
regulator of filament bundling for the formation of filo-
podia, which are actin-based protrusive sensory organelles
that contribute to the initiation of cell movement and cell
migration [4].
Fascin, is normally expressed in neuronal and mesen-
chymal cells and is low or absent in epithelia [4,6]. How-
ever, striking up-regulation of fascin has been reported
in several human malignant epithelial tumors including
colon, urinary bladder, pancreatic and lung carcinomas
[7-10]. Most of the immunohistochemical studies have
shown that fascin expression is correlated with the clinical
aggressiveness of tumors and with poor patient survival
[11]. Its down regulation reduces cell motility and invasive-
ness in esophageal squamous cell carcinoma [12]. How-
ever, it is not yet clear if fascin has an independent value as
a biomarker or not, because individual studies are not al-
ways consistent [13]. To date, only few immunohistochem-
ical studies have been conducted on fascin expression in
breast carcinomas. Such studies have reached discrepant
conclusions on their association with clinicopathological
prognostic parameters and metastasis [14-17].
A recent study using HCC (hepatocellular carcinoma)
cell lines showed that the migratory effect of fascin-1 on
HCC cells led to efficient invasion when assisted with
secretory factors from intrinsically highly invasive cells
such as MMP-2 (matrix metalloproteinase-2) and MMP-9,
which fascin-1 alone could not up regulate [18]. It has
been previously reported that tumor necrosis factor
α-induced MMP-9 production in cholangiocarcinoma
(CC) cells is concurrent with enhanced fascin-1 expres-
sion. As silencing of fascin-1expression abrogated MMP-9induction, fascin-1 was proposed be involved in the signal-
ing pathway for tumor necrosis factor α -related MMP-9
production [19]. The effects of fascin on cell invasiveness
involve both changes in cell motility as well as the activity
of matrix proteases [20].
Matrix metalloproteinases (MMPs), potent proteolytic
enzymes are known to play key roles in degradation
of basement membranes and extracellular matrix [21].
Within the MMP families, MMP-9 (92 kDa type IV colla-
ganase, gelatinase B) is able to degrade type IV collagen
that is abundant in basement membranes separating the
epithelial cells from the underlying stroma. Increased ex-
pression and activity of MMP - 9 in tumors lead to the
degradation of basement membranes, an essential step in
invasion and metastasis of malignant tumors [22]. Previ-
ous studies on the prognostic value of MMP-9 expression
in human cancers including breast carcinoma revealed
conflicting results [23-26].
To the best of our knowledge, no immunohistochemical
studies have been performed to assess the possible associ-
ation between fascin and MMP-9 in breast carcinoma.
This study is designed to correlate fascin and MMP-9 ex-
pression with clinicopathological prognostic parameters
in breast carcinoma and assess the relationship between
these two proteins.Methods
Tissue and patient data
The current study was conducted on 67 cases of invasive
ductal breast carcinoma which is the most common sub-
type of breast carcinomas. Cases were obtained from the
Archives of the Pathology Lab. of Ain-Shams University
Specialized Hospital. Such cases were diagnosed during
the period from January 2010 to January 2012. They
were obtained by modified radical mastectomy. The sur-
gical and histopathology reports were reviewed to deter-
mine age of patients, tumor size (greatest dimension),
estrogen-receptor (ER), progesterone-receptor (PR) and
HER2 status, as well as lymph nodal involvement. For
each patient, clinical stage at presentation was classi-
fied according to the 2003 American Joint Committee on
Cancer Staging System [27]. Haematoxylin and Eosin
stained slides were examined to re-evaluate and verify the
histopathologic diagnosis and grade (according to the
modified Bloom and Richardson method [28]). Only cases
with information for all the covariates were selected in
the analysis.Ethics statement
All patients who participated in this study signed a writ-
ten, informed consent before surgery. The study was ap-
proved by the Research Ethical Committee at Faculty of
Medicine, Ain Shams University.
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Four micrometer sections of formalin –fixed and paraffin-
embedded samples of 67 breast carcinoma cases were pre-
pared. They included the tumor and the adjacent normal
breast tissue. Immunohistochemical staining was per-
formed using primary antibodies; mouse monoclonal anti-
fascin (Clone: FCN01; 1:200 dilution; Thermo Fisher
Scientific Inc., Fremont, CA) and mouse monoclonal anti
MMP-9 (Clone: GE-213;1:200 dilution; Thermo Fisher
Scientific Inc., Fremont, CA). Avidin-Biotin immunoper-
oxidase complex technique was used according to Hsu
et al. [29] by applying the super sensitive detection kit
(Biogenex, CA, USA). The prepared tissue sections were
fixed on poly-L- lysine coated slides overnight at 37°C.
They were deparaffinized and rehydrated through graded
alcohol series. Then the sections were heated in a micro-
wave oven in 10 mM citrate buffer (pH 6.0) for 20 min.
After the blocking of endogenous peroxidase and in-
cubation in Protein Block Serum-Free Solution (Dako
Cytomation) for 20 min, the sections were incubated
overnight at 4°C with primary antibodies. Biotinylated
anti- mouse immunoglobulin and streptavidin conjugated
to horseradish peroxidase were then added. Finally, 3,3′ –
diaminobenzidine as the substrate or chromogen was used
to form an insoluble brown product. Finally, the sections
were counterstained with hematoxylin and mounted. Sec-
tions of Hodgkin’s disease and placenta were used as posi-
tive control for fascin and MMP-9 respectively. Negative
control sections were incubated with normal mouse
serum instead of the primary antibody.
Interpretation of immunohistochemical staining
Immunohistochemical analysis of fascin and MMP-9 was
blindly performed by the two pathologists (the authors)
without any prior knowledge of the clinicopathological
data. Any discrepancies were resolved by consensus using
a multi-headed microscope. Cytoplasmic expression of fas-
cin and MMP-9 was evaluated semi-quantitatively accord-
ing to the percentage of positive cells in at least five areas
at a magnification of 400×, and assigned to one of the four
following categories: 0, negative; 1, focally positive (1–10%
positive cells in the lesion); 2, moderately positive (11–
50%); and 3, markedly positive (more than 50%). Cases
with moderate or marked expression patterns (scores 2 or
3) were considered positive cases in this study [19]. The in-
tensity of expression of both proteins was assessed on the
basis of the predominant area of intensity (invasive fronts
of the tumor, invasive fronts and other areas or only other
areas).
Using immunohistochemistry for ER, PR, and HER2 as
a surrogate for expression profiling, the studied tumors
were classified according to Cheng et al. [30] as follows:
(a)Triple negative subtype [ER-, PR-, and HER2 -](b)HER2 subtype [HER2+/ER-PR-].
(c)Luminal A subtype [ER + and/or PR + plus HER2- with
histologic grade 1 or 2].
(d)Luminal B subtype [ER + and/or PR + plus HER2+ or
ER + and/or PR + plus HER2- with histologic grade 3].
Statistical analysis
Continuous variables are expressed as mean and Stand-
ard Deviation. Categorical variables are expressed as fre-
quencies and percent. Chi square and Fisher’s exact test
were used to examine the relationship between categorical
variables. Kappa statistics was used to compute the meas-
ure of agreement between two investigational methods;
Kappa’s values < 0 indicated no agreement while 0–0.20
indicated slight agreement, 0.21–0.40: fair, 0.41–0.60:
moderate, 0.61–0.80: strong and 0.81–1 revealed almost
perfect agreement. P < 0.05 was considered the cut-off
value of significance. All statistical procedures were car-
ried out using SPSS version 15 for Windows (SPSS Inc,
Chicago, IL, USA).
Results
Clinical and pathological data for the studied breast car-
cinoma cases are represented in Table 1. All the patients
are females, and their mean age is 55.3 years (Standard
deviation, ± 11.3 ; range, 35–76 years).
Expression of fascin and its relationship with
clinicopathological parameters
In normal breast tissue, fascin expression was observed
in myoepithelial cells and luminal cells of few ducts and
acini (Figure 1a). Eight (12%) out of 67cases of invasive
ductal carcinomas showed adjacent ductal carcinoma
in situ (DCIS). Fascin expression was present in myoe-
pithelial cells of the in situ component (Figure 2a). More-
over, out of the eight cases, only two cases (25%) revealed
fascin expression in ductal epithelial cells of in situ car-
cinoma lesions (Figure 2b). However, 29 (43.28%) out
of 67 invasive ductal breast carcinomas exhibited cyto-
plasmic fascin expression (Figures 1b and 2b). Fascin was
expressed in endothelial cells of the stroma surrounding
neoplastic epithelial cells. Moreover, it was also expressed
by histiocytes and lymphoid cells. There was a statis-
tical significant relationship between fascin expression
and lymph node metastases (p = 0.001) and advanced
tumor stage (p = 0.004). Moreover, there was an inverse
correlation between fascin expression and both estrogen
receptor (p = 0.002) and progesterone receptor (p = 0.001)
hormonal status. However, no statistical correlation was
found between fascin expression and patients’ age (p =
0.193), tumor size (p = 0.058), histological grade (p = 0.111)
or HER2 status (p = 0.246) (Figure 3). The relationship be-
tween fascin expression and clinicopathological parame-
ters is shown in Table 1.
Table 1 Relationship between fascin and MMP-9 expressions and clinicopathological parameters of the studied breast
carcinomas (n = 67)
Fascin expression MMP-9 expression
Variable n (%) Negative
n = 38
Positive
n = 29
P value Negative
n = 33
Positive
n = 33
P value
Age (years)
≤ 50 22 (33) 10 (45.5%) 12 (54.5%) 0.193* 10 (45.5%) 12 (54.5%) 0.664*
>50 45 (67) 28 (62.2%) 17 (37.8%) (NS) 23 (51.1%) 22 (48.9%) (NS)
Tumor size (cm)
≤5 41 (61.19) 27 (65.9%) 14 (34.1%) 0.058* 24 (58.5%) 17 (41.5%) 0.056*
>5 26 (38.81) 11 (42.3%) 15 (57.7%) (NS) 9 (34.6%) 17 (65.4%) (NS)
Grades
I 7 (10.4) 3 (42.9%) 4 (57.1%) 0.111** 2 (28.6%) 5 (71.4%) 0.088**
II 44 (65.7) 29 (65.9%) 15 (34.1%) (NS) 26 (59.1%) 18 (40.9%) (NS)
III 16 (23.9) 6 (37.5%) 10 (62.5%) 5 (31.2%) 11 (68.8%)
Lymph nodal status
Node – 24 (35.8) 20 (83.3%) 4 (16.7%) 0.001* 18 (75.0%) 6 (25.0%) 0.002*
Node + 43 (64.2) 18 (41.9%) 25 (58.1%) (S) 15 (34.9%) 28 (65.1%) (S)
Stage
I 18 (26.87) 15 (83.3%) 3 (16.7%) 0.004* 14 (77.8%) 4 (22.2%) 0.005*
II 29 (43.28) 17 (58.6%) 12 (41.4%) (S) 14 (48.3%) 15 (51.7%) (S)
III 20 (29.85) 6 (30.0%) 14 (70.0%) 5 (25.0%) 15 (75.0%)
Estrogen receptor
Negative 21 (31.3) 6 (28.6%) 15 (71.4%) 0.002* 5 (23.8%) 16 (76.2%) 0.005*
Positive 46 (68.7) 32 (69.6%) 14 (30.4%) (S) 28 (60.9%) 18 (39.1%) (S)
Progesterone receptor
Negative 24 (35.8) 7 (29.2%) 17 (70.8%) 0.001* 6 (25.0%) 18 (75.0%) 0.003*
Positive 43 (64.2) 31 (72.1%) 12 (27.9%) (S) 27 (62.8%) 16 (37.2%) (S)
HER2
Negative 55 (82.1) 33 (60.0%) 22 (40.0%) 0.246* 30 (54.5%) 25 (45.5%) 0.064*
Positive 12 (17.9) 5 (41.7%) 7 (58.3%) (NS) 3 (25.0%) 9 (75.0%) (NS)
*Chi-square test.
**Fisher exact test.
S: significant.
NS: non-significant.
n = number of cases.
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clinicopathological parameters
The normal breast tissue adjacent to the tumor was nega-
tive for MMP-9 expression (Figure 1c). Three (37.5%) out
of the eight cases of invasive ductal carcinoma with adja-
cent in situ ductal component revealed positive MMP-9
expression in the in situ carcinoma lesions (Figure 2c)
while the rest of the cases showed negative expression
(Figure 2d). The expression pattern of MMP-9 was cyto-
plasmic in both cancer cells and stromal cells (Figure 1d).
However, MMP-9 staining in stromal cells was weak;
therefore its staining in stromal cells was not assessed.
Thirty four (50.75%) out of 67 breast carcinoma samples
were immunoreactive for MMP-9. There was a significantcorrelation between MMP-9 expression and lymph node
metastases (p = 0.002), advanced tumor stage (p = 0.005)
as well as both estrogen receptor negative (p = 0.005)
and progesterone receptor negative (p = 0.003) hormo-
nal status (Figure 4). However, no statistical association
was detected between MMP-9 expression and patients’
age (p = 0.664), tumor size (p = 0.056), histological grade
(p = 0.088) or HER2 status (p = 0.064). These data are also
summarized in Table 1.
Relationship between fascin and MMP-9expression and
breast cancer molecular subtypes
Triple negative subtype and HER2 subtype showed a sig-
nificant higher rate of fascin and MMP-9 expression
Figure 1 Fascin and MMP-9 expressions in normal breast tissue and invasive ductal carcinomas. a: Moderate fascin expression in the
myoepithelial cells and luminal cells of few normal acini (IHC × 400). b: Positive cytoplasmic fascin expression in malignant cells (IHC × 400).
c: Negative MMP-9 expression in normal breast tissue (IHC × 400). d: Positive cytoplasmic MMP-9 expression of malignant cells with weak
expression of stromal cells (IHC × 400).
Figure 2 Fascin and MMP-9 expression in invasive ductal carcinomas with adjacent in situ component. (a): Positive cytoplasmic fascin
expression in the myoepithelial cells of the in situ component (IHC × 200). (b): Positive cytoplasmic fascin expression in the in situ carcinoma
lesions as well as the adjacent invasive carcinoma (IHC × 200). (c): Positive cytoplasmic MMP-9 expression in the in situ carcinoma lesions (IHC × 200).
(d): Positive cytoplasmic MMP-9 expression in invasive carcinoma and negative expression in the in situ carcinoma lesions (IHC × 200).
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Figure 3 Relationship between fascin expression and poor
prognostic parameters in breast carcinoma.
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spectively). Data for fascin and MMP-9 expression in
different breast cancer molecular subtypes are summa-
rized in Table 2.
Agreement between fascin and MMP-9 expressions in
breast carcinoma
Comparing fascin and MMP-9 expressions in each case, out
of 29 cases with positive fascin expression, 27 cases (93.1%)
showed also positive MMP-9 immunoreactivity. There was
a significant strong agreement between fascin and MMP-9
expressions (kappa = 0.723, p = 0.0001) (Table 3). Next, the
intensities of immunohistochemical staining of fascin and
MMP-9 were compared in the invasive front versus other
areas in each tumor. As shown in Table 4, 75.9% of breast
carcinomas with positive fascin expression showed more
intense immunostaining at the invasive fronts compared
with other areas (Figure 5a and b). Similarly, 67.7% of
breast carcinoma samples showing positive MMP-9 ex-
pression were found to have intense expression at the in-
vasive fronts (Figure 5c and d). Moreover, there was a
significant moderate agreement between fascin and MMP-9
regarding the site of predominant intensity (kappa = 0.434,
p = 0.012) (Table 5).Figure 4 Relationship between MMP-9 expression and poor
prognostic parameters in breast carcinoma.Discussion
Metastasis remains the main cause of cancer mortalities
[1], stressing the need to understand the cellular and
molecular mechanisms that regulate this process. It is a
complex process where cytoskeletal proteins were re-
ported to regulate multiple cellular processes including
morphological changes and motility, which are critical
steps for metastasis [31].
Fascin is an actin-bundling motility-associated protein
that plays an important role in the assembly of cell-
motility structures [32]. Therefore, it is possible that fascin
expression in cancer cells may lead to a more clinically
aggressive course through augmented cell motility and
enhanced metastatic potential, a finding supported by
in vitro observations [33]. Most of studies have shown that
fascin expression is correlated with the clinical aggressive-
ness of tumors and with poor patient survival. In studies
of breast cancer, some researchers have shown that fascin
expression increases in more advanced tumors [15], but
the results of other studies have not agreed with those
findings [14].
In the current study, 43.28% of invasive ductal breast
carcinomas showed positive fascin expression. However,
in the adjacent normal breast tissue, fascin expression
was observed in myoepithelial cells and luminal cells of
few ducts and acini. These results are consistent with
previous studies showing striking up-regulation of fascin
in a variety of malignancies including breast carcinoma
[7-10,17], while normal epithelia exhibited very low
levels of expression [14,16]. In agreement with Onodera
et al. [19], we found positive fascin expression in DCIS
of 25% of invasive ductal carcinomas with in situ com-
ponent. Only few studies, investigating fascin expression
in breast cancer tissues, have been conducted showing
different rates of expression. Grothey et al. [14] found
that 70% of estrogen receptor negative and 50% of pro-
gesterone receptor negative breast cancer were positive
for fascin expression. Yoder et al. [15] observed positive
fascin immunoreactivity in 16% of the invasive breast
carcinomas. Rodriguez-Pinilla et al. [16] detected fascin
expression in 25.1% of sporadic invasive breast carcinomas
and in 83.3% and 16.7% BRCA1- and BRCA2-associated
carcinomas, respectively. Al Alwan et al. [17] demon-
strated fascin in the tumor cells of 40.84% of invasive
ductal breast carcinoma patients.
Heterogeneity in the results was apparent within breast
carcinoma studies. This could be due to difference in the
commercial company supplying the primary antibody, and
the method of immunohistochemical staining. Further-
more, it should be noted that each study included differ-
ent histological types of breast carcinomas. Grothey et al.
[14] investigated hormone receptor -negative breast can-
cer. Yoder et al. [15] studied primary node-positive and
node-negative invasive breast carcinomas, which included
Table 2 Relationship between fascin and MMP-9 expression and breast cancer molecular subtypes (n = 67)
Molecular subtype Fascin expression MMP-9 expression
Positive Negative P-value Positive Negative P-value
n (%) n (%) n (%) n (%)
Triple negative 12 (17.9) 11 (91.7) 1 (8.3) 0.0007* (S) 10 (83.3) 2 (16.7) 0.0143* (S)
HER2 subtype 9 (13.4) 4 (44.4) 5 (55.6) 6 (66.7) 3 (33.3)
Luminal subtype 46 14 (30.4) 32 (69.6) 18 (39.1) 28 (60.9)
-Luminal A 33 (49.3)
-Luminal B 13 (19.4)
*Chi-square test.
S: significant.
n = number of cases.
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omas, mucinous carcinomas and medullary carcinomas.
Rodriguez-Pinilla et al. [16] investigated node-negative
sporadic and hereditary invasive breast carcinomas. Al-
Alwan et al. [17] as well as our current research studied
invasive ductal carcinoma only.
In our work, we found a significant relationship between
fascin expression and negative prognostic factors as lymph
node metastases and advanced tumor stage. Concomitant
with these results, Al Alwan et al. [17] found a significant
correlation between fascin expression and lymph nodal
metastases and Yoder et al. [15] reported a significant as-
sociation between fascin expression and advanced tumor
stage. However, Yoder et al. [15] as well as Grothey et al.
[14] did not find any significant relationship between
fascin expression and lymph nodal status. Moreover, the
later [14] did not find any correlation with advanced
tumor stage.
The present research confirms a statistically significant
inverse relationship between fascin expression and estro-
gen receptor and progesterone receptor status. These
observations are in line with previous studies [14-17].
Hormone receptor–negative breast cancers traditionally
have a worse prognosis and fewer available treatment
options (ineffectiveness of hormonal therapy) compared
with hormone receptor–positive tumors [34-36]. It is in-
teresting that hormone receptor–negative breast cancers
also display increased cell motility in vitro [37,38]. In a
study examining the ability of breast cancer cell lines toTable 3 Agreement between fascin and MMP-9 expressions
in breast carcinoma cases (n = 67)
Fascin expression
Negative
(n = 38)
Positive
(n = 29)
Kappa p- value
MMP-9 expression
Negative (n = 33) 31 (81.6%) 2 (6.9%) 0.723 0.0001
Positive (n = 34) 7 (18.4%) 27 (93.1%)
n = number of cases.
P-value < 0.0001: very highly significant.penetrate into a collagen-fibroblast matrix, cells express-
ing mRNA for estrogen receptor showed a noninvasive
phenotype, whereas cells lacking estrogen receptor mRNA
were shown to be highly invasive [38]. Yoder et al. [15]
suggested a connection between the expression of fascin
and the absence of hormone receptors, increased cell mo-
tility, and decreased survival in human breast cancers. It is
conceivable that fascin may serve as a downstream cyto-
skeletal effector contributing to the more aggressive/
malignant phenotype of hormone receptor -negative
breast cancer.
Interestingly, no association was identified in the present
study between fascin expression and patients’ age or tumor
size. These observations are in accordance with Yoder
et al. [15] and Rodriguez et al. [16]. However, in a recent
study, fascin correlated significantly with tumor size [17].
There was no significant relationship between fascin
immunoreactivity and tumor grade. A similar absence of
correlation has also been noted by Grothey et al. [14]
and Al- Alwan et al. [17] although Yoder et al. [15] and
Rodriguez et al. [16] reported a significant positive asso-
ciation between fascin expression and tumor grade.
In vitro, studies revealed that fascin exhibits highly in-
creased levels in breast cancer cell lines over-expressing
the receptor tyrosine kinase and prognostic indicator c-
erbB-2/HER-2, and that such cells exhibit dramatically
increased cell dynamics and in vitro motility [39]. The
data presented in our research failed to reveal any asso-
ciation between fascin and HER2 status in tissue samples
concomitant with Yoder et al. [15], Rodriguez et al. [16]
and Al- Alwan et al. [17]. This could be due to limited
population size or an institutional bias. Alternatively, the
forced overexpression of this receptor in cell cultures by
transfection may represent an artificial system, which
may not well reflect the biological complexity of HER2
gene amplification and protein overexpression occurring
in vivo.
By using siRNA technology, Xie et al. [20] have suc-
cessfully silenced fascin gene in EC109 cells, an esopha-
geal squamous cell carcinoma cell line. They found that
Table 4 Intensities of fascin and MMP-9 expressions in breast carcinoma cases
Intensity of expression on the basis of the predominant area
Invasive front > other areas Invasive front = other areas Invasive front < other areas
Fascin expression (29)* 22 (75.9%) 6 (20.7%) 1 (3.4%)
MMP-9 expression (34)** 23 (67.7%) 10 (29.4%) 1 (2.9%)
*Breast carcinoma cases with positive fascin expression.
**Breast carcinoma cases with positive MMP-9 expression.
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mation of surface protrusions that play essential roles in
cell motility. Besides the decreased formation of protru-
sions, Xie et al. [20] suggested another possible mechan-
ism for fascin effect on cell invasiveness, as shown in the
gelatin zymography, which was the decreased activity of
extracellular matrix proteases as MMP-2 and MMP-9.
Such proteases digest collagen type IV and other compo-
nents of the basement membrane and play a key role in
local invasiveness and the formation of distant metasta-
ses by malignant tumors [22]. Xie et al. [20] postulated
that the effects of fascin on cell invasiveness involve both
changes in cell motility as well as the activity of matrix
proteases. Furthermore, Onodera et al. [19] showed that
fascin was responsible for the overproduction of MMP-9
in cholangiocarcinoma (CC), raising a possibility that
fascin relates not only to increased cell motility but also
to stromal degradation during the invasion of CC. InFigure 5 Invasive ductal breast carcinomas. a: Enhanced fascin expressi
with higher magnification power showing positive cytoplasmic fascin expr
MMP-9 expression at the tumor–host border (IHC × 100). d: The same field
MMP-9 expression of malignant cells (IHC × 200).addition, the migratory effect of fascin-1 on hepatocellular
carcinoma cells led to efficient invasion when assisted
with secretory factors from intrinsically highly invasive
cells such as MMP-9, which fascin-1 alone could not up
regulate. Concomitant with these observations, our study
revealed a significant strong agreement between fascin
and MMP-9 expressions in breast carcinoma cases. To the
best of our knowledge, this is the first study to investigate
the relationship between immunohistochemical expres-
sion of fascin and MMP-9 in breast cancer.
In the current research more intense expression of fas-
cin and MMP-9 was observed at the invasive fronts
compared with other areas of tumor. Moreover, a signifi-
cant moderate agreement between fascin and MMP-9
was found regarding the site of predominant intensity.
These observations are in agreement with Onodera et al.
[19]. In addition, Grothey et al. [14] previously observed
that fascin staining is often enhanced at the leadingon at the leading edge of the tumor (IHC × 100). b: The same field
ession of malignant cells and endothelial cells (IHC × 200). c: Enhanced
with higher magnification power showing positive cytoplasmic
Table 5 Agreement between intensities of fascin and MMP-9 expressions in 27 cases positive for both proteins
Fascin expression Kappa P
Invasive front < other areas Invasive front = other areas Invasive front > other areas
N % N % N %
MMP-9 Invasive front < other areas 0 0.0% 1 3.7% 0 0.0% 0.434 0.012 (S)
Invasive front = other areas 1 3.7% 4 14.8% 4 14.8%
Invasive front > other areas 0 0.0% 1 3.7% 16 59.3%
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pathogenic factor for tumor cell invasion. Onodera et al.
[19] demonstrated that overexpression of MMP-9 in-
duced by TNF-α was also inhibited by fascin siRNA, im-
plying that TNF-α-induced MMP-9 overexpression is
mediated by fascin. Interestingly, they found that macro-
phages positive for TNF-α were commonly observed at
the invasive front of cholangiocarcinoma compared with
the central part of CC. Such locally released TNF- α
from macrophages around the invasive front of CC may
be responsible for such overproduction of fascin and
then MMP-9. These findings may explain the correlated
dense expression pattern of fascin and MMP-9 in breast
carcinoma tissues at the invasive fronts, as shown in the
current study.
Many previous studies have been conducted to re-
search MMP-9 expression in human cancers, including
breast cancer, but the results are still controversial. In
the present study, MMP-9 expression was detected in
50.75% of breast carcinoma cases with weak expression
in stromal cells. In contrast, the adjacent normal breast
tissue did not express MMP-9. These results are consist-
ent with Scorilas et al. [24] who observed MMP-9 stain-
ing primarily in cancer cells, and to a lesser degree in
surrounding stromal cells but not in normal breast tis-
sue. However, Pellikainen et al. [40] observed MMP-9 in
both tumor cells and stromal fibroblasts and inflamma-
tory cells. In addition, benign breast epithelium and vas-
cular endothelium stained positively for MMP-9.
In the current research, 37.5% of invasive ductal car-
cinomas with adjacent in situ component revealed posi-
tive MMP-9 expression in the in situ carcinoma lesions.
This result is in agreement with Kim et al. [41] who found
MMP-9 mRNA expression in 50% of DCIS and 44% of in-
vasive ductal carcinoma cases. They added that MMP
mRNA expression levels suggest that an invasive potential
of breast carcinoma is already obtained before morpho-
logically overt invasive growth is observed.
In our study, there was a significant correlation be-
tween MMP-9 expression and lymph node metastases,
advanced tumor stage as well as estrogen receptor nega-
tive and progesterone receptor negative hormonal status.
Similar to these findings, Fan et al. [25] observed that
MMP-9 overexpression was higher in breast cancers
with lymph node metastases than those without lymphnode metastases. They added that increased expression of
MMP-9 protein was correlated with high TNM classifica-
tion. Furthermore, Przybylowska et al. [42] and Slattery
et al. [43] found a significant relationship between MMP-9
and ER-/PR- tumors. In addition, Liu et al. [44] observed a
significant association between basal like breast cancer
and MMP-9. In contrast, Zhang et al. [23] noted that high
MMP-9 expression in tumor cells was not associated with
any clinicopathological parameters or immunohistochemi-
cal expression of ER and PR. Scorilas et al. [24] found that
MMP-9 negative tumors were obtained from patients who
were diagnosed with stage III-IV disease and Grieu et al.
[45] observed that MMP-9 21562 polymorphism was as-
sociated with ER positive tumors.
In the current research, no statistical association was de-
tected between MMP-9 expression and patients’ age,
tumor size, histological grade or HER2 status. Parallel to
these results, Scorilas et al. [24] observed no significant as-
sociation between MMP-9 and tumor grade and Zhang
et al. [23] found no correlation between MMP-9 and
c-erbB2 (HER2). In contrast, Li et al. [46] detected a sig-
nificant relationship between positive MMP-9 immuno-
staining and higher tumor grade. Moreover, Fan et al. [25]
and Przybylowska et al. [42] found that MMP-9 protein
was positively associated with tumor size. The different re-
sults between our present study and others might be due
to differences in sample size, methods of scoring criteria,
and the antibodies used to evaluate expression.
Regarding breast cancer molecular subtypes, in the
current research, triple negative breast cancers had the
highest rate of fascin and MMP-9 expression. However,
luminal breast cancer had the lowest rate of expression.
It is well established in the literature that triple negative
subtype is an independent prognostic factor of distant
metastasis due to its strong invasive ability and metasta-
sis ability [47]. It represents one of the most aggressive
phenotype with discrete risk factors and ominous prog-
nostic significance [48]. On the other hand, luminal sub-
type of breast cancer has better prognosis than other
molecular subtypes [49]. Fascin and MMP-9 might be
markers of aggressive behaviour in breast cancer.
Conclusion
In conclusion, both fascin and MMP-9 proteins are asso-
ciated with parameters of poor prognosis. Given fascin’s
Youssef and Hakim Diagnostic Pathology 2014, 9:136 Page 10 of 11
http://www.diagnosticpathology.org/content/9/1/136role in enhancing cell motility, the data presented here
suggests that fascin expression may contribute to a more
aggressive clinical course and thus an enhanced metastatic
potential in ER/PR-negative breast cancer. Moreover,
overexpression of MMP-9 might play a critical role in deg-
radation of extracellular matrix to enhance the invasive
and metastatic capacity of breast cancer. In addition,
dense expression pattern of fascin and MMP-9 in breast
carcinoma tissues at the invasive fronts confirms their role
as pathogenic factors for tumor cell invasion. The current
study reports for the first time the direct relationship be-
tween fascin and MMP-9 expression in breast cancer. This
finding supports the role of fascin in cell invasiveness by
activating matrix proteases besides increasing cell motility
as postulated by previous studies. Finally, Fascin and
MMP-9 may represent potential therapeutic targets for
patients with breast cancer especially those with hormone
receptor–negative status.
A limitation of this study is that the cases were derived
from a regional population base that lacks breast cancer
outcomes including response to different modalities of
therapy and disease free survival. Therefore, further lar-
ger studies are still needed to explore the direct relation
of facsin and MMP-9 expression to breast cancer pa-
tients’ survival and their prognostic value within differ-
ent treatment modality subsets.
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